
FONAR Corporation FONR
$ 18.51
0.52%
Quarterly report 2025-Q4
added 02-13-2026
FONAR Corporation Book Value 2011-2026 | FONR
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value FONAR Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 146 M | 135 M | 126 M | 118 M | 102 M | 82.9 M | 60.8 M | 50.8 M | 45.9 M | 37.8 M | 11.1 M | 5.87 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 146 M | 5.87 M | 76.9 M |
Quarterly Book Value FONAR Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 163 M | 161 M | 160 M | 159 M | 159 M | 157 M | 156 M | 154 M | 151 M | 148 M | 147 M | 146 M | 144 M | 142 M | 139 M | 135 M | 135 M | -50.3 M | -53.2 M | 126 M | -54 M | -46.6 M | -44 M | 118 M | -15.4 M | -13 M | -13.3 M | -16.1 M | -16.1 M | -15.2 M | -15.4 M | -15.9 M | -15.9 M | -19.3 M | -20.5 M | -24.1 M | -24.1 M | -24.8 M | -26 M | -25.7 M | -25.7 M | -28.8 M | -30.7 M | -30.9 M | -30.9 M | -35 M | -35.3 M | -35.4 M | -35.4 M | -22.7 M | -22.8 M | -22.5 M | -22.5 M | -24.3 M | -25.7 M | -25.7 M | -25.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 163 M | -54 M | 31.1 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Orthofix Medical
OFIX
|
450 M | $ 11.78 | 0.51 % | $ 467 M | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.35 | 4.12 % | $ 335 M | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Penumbra
PEN
|
1.43 B | $ 335.59 | 0.4 % | $ 13.1 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 221.0 | -2.0 % | $ 15.5 B | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Profound Medical Corp.
PROF
|
31.2 M | $ 5.66 | 9.89 % | $ 180 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
IRadimed Corporation
IRMD
|
94.6 M | $ 101.26 | 0.29 % | $ 1.29 B | ||
|
AVITA Medical
RCEL
|
-16.6 M | $ 3.96 | 3.13 % | $ 110 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 36.45 | -0.37 % | $ 1.13 B | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Sintx Technologies
SINT
|
2.93 M | $ 2.6 | 1.17 % | $ 7.21 M | ||
|
NanoVibronix
NAOV
|
627 K | - | - | $ 1.08 M | ||
|
Electromed
ELMD
|
43.2 M | $ 24.7 | - | $ 209 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Smith & Nephew plc
SNN
|
5.26 B | $ 32.29 | 0.39 % | $ 23.8 B | ||
|
MiMedx Group
MDXG
|
257 M | $ 4.11 | -0.61 % | $ 607 M | ||
|
Sensus Healthcare
SRTS
|
48.1 M | $ 4.18 | 5.43 % | $ 68.2 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
11.1 M | $ 0.67 | -3.71 % | $ 36.5 M | ||
|
Aethlon Medical
AEMD
|
5.12 M | $ 2.31 | 6.94 % | $ 3.61 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Stryker Corporation
SYK
|
22.4 B | $ 325.47 | -0.95 % | $ 124 B | ||
|
Tactile Systems Technology
TCMD
|
219 M | $ 27.52 | 2.46 % | $ 629 M | ||
|
InspireMD
NSPR
|
55.2 M | $ 1.79 | - | $ 115 M | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 11.4 | -0.7 % | $ 1.54 B | ||
|
Myomo
MYO
|
11.4 M | $ 0.7 | 0.47 % | $ 29.3 M | ||
|
Tandem Diabetes Care
TNDM
|
155 M | $ 24.0 | -2.08 % | $ 1.63 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
189 M | $ 2.34 | -2.71 % | $ 137 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.7 | -5.37 % | $ 138 M | ||
|
Quanterix Corporation
QTRX
|
296 M | $ 3.94 | 3.14 % | $ 168 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 16.16 | 1.57 % | $ 379 M | ||
|
Outset Medical
OM
|
127 M | $ 3.48 | -1.42 % | $ 52.9 K |